Interim report January - September 2010

Interim report January - September 2010

Third quarter
2010                                                                    
                             

  · Net sales increased by 21 % to 109.5 MSEK (90.6). At comparable
exchange rates sales increased by 24 %.
  · The operating result amounted to 4.8 MSEK (2.0).
  · The result after tax amounted to 4.7 MSEK (1.2).
  · Earnings per share amounted to 0.06 SEK (0.01).
  · The cash flow from operating activities amounted to 7.0 MSEK (5.0).
  · Net cash at September 30, 2010 amounted to 174.9 MSEK (327.2).
  · During the quarter 4,299,625 own shares were purchased. At the
balance sheet date September 30 Biotage owned a total of 8,741, 612
shares, acquired for 63.6 MSEK, i.e. an average share price of 7.27 SEK.

January - September 2010  

  · Net sales increased by 6 % to 312.8 MSEK (294.6). At comparable
exchange rates net sales increased by 14 %.
  · The operating result amounted to 17.1 MSEK (-13.2).
  · The result after tax amounted to 14.5 MSEK (-14.6).
  · Earnings per share amounted to 0.17 SEK (-0.16).
  · The cash flow from operating activities amounted to 45.5 MSEK
(17.8).
  · MIP Technologies AB was acquired on April 30, 2010.
  · The product lines RapidTrace® and TurboVap® and associated assets
were acquired on May 25 from Caliper Life Sciences, Inc.
  · Dividends to shareholders were paid to the amount of 17.3 MSEK.

For further information, please contact: 

Torben Jörgensen, President and CEO, phone: +46 707 49 05
84                                               

Mats-Olof Wallin, CFO, phone: +46 705 93 52 73 
 

The information in this press release is of the kind that Biotage AB
(publ) is required to make public according to the Securities Business
Act and/or the Financial Instruments Trading Act.  The information was
released for publication at 12.00 on October 26, 2010.

About Biotage
Biotage offers solutions, knowledge and experience in the areas of
analytical chemistry and medicinal chemistry. The customers include the
world's largest pharmaceutical and biotech companies, and leading
academic institutes. The company is headquartered in Uppsala and has
subsidiaries in the US, UK and Japan. Biotage has 269 employees and had
sales of 394.1 MSEK in 2009. Biotage is listed on the NASDAQ OMX Nordic
Stockholm stock exchange. Website:
www.biotage.com (http://www.biotage.com/)
Interim report January - September 2010

Attachments
